{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:49Z","timestamp":1790179669933,"version":"4.1.0"},"reference-count":11,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.271459","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:10:19Z","timestamp":1769706619000},"page":"681-686","source":"Crossref","is-referenced-by-count":2,"title":["Feasibility of [\n                    <sup>89<\/sup>\n                    Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Joni J.","family":"Nijveldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Af Bur\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Jussing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim N.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kistner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimma","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Tzortzakakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026050105301232000_67.5.681.1","doi-asserted-by":"crossref","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","journal-title":"Biochem Pharmacol."},{"key":"2026050105301232000_67.5.681.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30689-8"},{"key":"2026050105301232000_67.5.681.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"2026050105301232000_67.5.681.4","doi-asserted-by":"crossref","first-page":"102257","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis","volume":"99","author":"Boman","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"2026050105301232000_67.5.681.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.117218"},{"key":"2026050105301232000_67.5.681.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268289"},{"key":"2026050105301232000_67.5.681.7","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-22-1547","article-title":"ImmunoPET imaging with 89Zr-Labeled atezolizumab enables in\u00a0vivo evaluation of PD-L1 in tumorgraft models of renal cell carcinoma","volume":"28","author":"Mulgaonkar","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026050105301232000_67.5.681.8","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med."},{"key":"2026050105301232000_67.5.681.9","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/cancers15102708","article-title":"[89Zr]-Atezolizumab-PET imaging reveals longitudinal alterations in PDL1 during therapy in TNBC preclinical models","volume":"15","author":"Massicano","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026050105301232000_67.5.681.10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40658-024-00621-7","article-title":"How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans","volume":"11","author":"Wijngaarden","year":"2024","journal-title":"EJNMMI Phys."},{"key":"2026050105301232000_67.5.681.11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/neuonc\/noae190","article-title":"Imaging PD-L1 in the brain\u2014journey from the lab to the clinic","volume":"27","author":"Dar","year":"2025","journal-title":"Neuro Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:30:36Z","timestamp":1777638636000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.271459"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271459","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}